CORE--CLINICAL AND LABORATORY

临床/实验室核心的牙科和医学临床医生将看到 所有由流行病学队列转介的患者都进行队列分析并确认诊断结果。 从这些转介和其他来源的患者转介中，他们将 继续建立特定口腔病变患者的临床队列 为了分析它们与艾滋病发展的关系，并 其他标记物/预测物。他们将获得样本和活组织检查 来自具有良好特征的口腔疾病患者的方案4和5的研究 正在研究的损伤。核心员工将负责临床 研究患者图表和记录，以进行预约和后续呼叫 关于结果，用于标本处理和存储以及获取 将标本交给项目4和项目5的调查人员。他们会染上污渍， 切片，处理样本和活检组织，维护病理和其他 临床实验室数据，进行Epstein-Barr的原位杂交 病毒以确认毛状白斑的诊断并提供 电子显微镜服务。临床/实验室核心调查人员 将继续研究口腔癌的临床和病理特点 艾滋病毒感染的表现，并与项目1、4和 5名调查人员，将继续报告新功能并探索其 病因、发病机制和治疗反应。部分内容 调查人员在核心和项目中的责任将是 继续记录和发布这些新的发现，并构思和测试 关于这群令人着迷和具有挑战性的 疾病。

The dental and medical clinicians of the Clinical/Laboratory Core will see all patients referred by the epidemiology cohorts and validate diagnoses. From these referrals and other sources of patient referrals, they will continue to build clinical cohorts of patients with specific oral lesions in order to analyze their relationship to the development of AIDS and to other markers/predictors. They will obtain samples and biopsies for the studies in Projects 4 and 5 from well-characterized patients with the oral lesions being studied. The core staff will be responsible for clinical research patient charts and records, for appointments, for follow-up calls concerning outcome, for specimen handling and storage and for getting specimens to Project 4 and 5 investigators. They will stain smears and sections, handle samples and biopsy tissue, maintain pathology and other clinical laboratory data, perform in situ hybridization for Epstein-Barr virus to confirm the diagnosis of hairy leukoplakia and provide electronmicroscopy services. The Clinical/Laboratory Core investigators will continue to study the clinical and pathological features of the oral manifestations of HIV infection and, in conjunction with Project 1, 4 and 5 investigators, will continue to report new features and to explore their etiology, pathogenesis and response to therapy. Part of the responsibilities of the investigators in the Cores and Projects will be to continue to document and publish such new findings and to conceive and test new hypotheses concerning this fascinating and challenging group of diseases.